INCB 54828-203 (FIGHT 203)

INCB 54828-203 (FIGHT 203)

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) 


Study treatment

Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy. Participants will receive either the intermittent dose (as written) or continuous dosing.


Inclusion criteria


Exclusion criteria


Participating sites

Link